Table 1.
Demographic, Clinical and Physiological Characteristics at Pre-Randomization Baseline
| Variable | Home-based (n = 53) | Supervised (n = 51) | Sertraline (n = 49) | Placebo (n = 49) | Cohort (n = 202) | P-value |
|---|---|---|---|---|---|---|
| Age, years | 52.8 (7.9) | 51.1 (7.0) | 51.8 (7.7) | 51.2 (7.8) | 51.7 (7.6) | .386 |
| Sex, female, n (%) | 39 (74) | 39 (76) | 37 (76) | 38 (78) | 153 (76) | .980 |
| Black, n (%) | 14 (26) | 12 (24) | 12 (25) | 14 (29) | 52 (26) | .802 |
| Caucasian, n (%) | 35 (66) | 36 (71) | 35 (71) | 31 (63) | 137 (68) | |
| Other Ethnicity, n (%) | 4 (8) | 3 (5) | 2 (4) | 4 (8) | 13 (6) | |
| Antihypertensive Medications, n (%) | 10 (19) | 11 (22) | 11 (22) | 15 (31) | 47 (32) | .487 |
| Diabetes, n (%) | 4 (8) | 3 (6) | 3 (6) | 4 (8) | 14 (7) | .895 |
| Current Tobacco Use, n (%) | 8 (15) | 7 (14) | 9 (18) | 8 (16) | 32 (16) | .756 |
| Systolic Blood Pressure, mm Hg | 122 (16) | 122 (17) | 126 (19) | 127 (18) | 124 (17) | .270 |
| Diastolic Blood Pressure, mm Hg | 78 (9) | 79 (9) | 81 (10) | 80 (9) | 79 (9) | .364 |
| Lipid-Lowering Medications, n (%) | 6 (11) | 1 (2) | 4 (8) | 7 (14) | 19 (9) | .067 |
| Total Cholesterol, ng/ml | 204 (36) | 207 (48) | 210 (40) | 209 (37) | 207 (40) | .973 |
| High Density Lipoprotein, ng/ml | 56 (13) | 55 (14) | 58 (21) | 58 (15) | 57 (16) | .820 |
| Low Density Lipoprotein, ng/ml | 123 (31) | 118 (31) | 124 (33) | 124 (37) | 122 (34) | .831 |
| Flow-Mediated Dilation, % | 5.3 (3.6) | 6.0 (4.3) | 6.1 (4.9) | 6.3 (4.5) | 5.9 (4.3) | .361 |
| Intima Medial Thickness, mm | 0.64 (0.15) | 0.60 (0.11) | 0.64 (0.13) | 0.64 (0.13) | 0.63 (0.13) | .341 |
| ASCVD Risk Score, 10-year % Risk | 5.0 (7.1) | 3.9 (5.5) | 5.4 (6.9) | 4.5 (4.7) | 4.7 (6.1) | .751 |
Treatment group differences were assessed using general linear models for continuous variables and chi-square tests for categorical variables.